Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.

Journal of neuro-oncology - 1 Jan 2020

Berberich Anne, Schmitt Lara-Marie, Pusch Stefan, Hielscher Thomas, Rübmann Petra, Hucke Nanina, Latzer Pauline, Heßling Bernd, Lemke Dieter, Kessler Tobias, Platten Michael, Wick Wolfgang

Abstract excerpt

BACKGROUND: Anaplastic lymphoma kinase (ALK) is expressed in ~ 60% of glioblastomas and conveys tumorigenic functions. Therefore, ALK inhibitory strategies with alectinib are conceivable for patients with glioblastoma. The aims of this preclinical study were to investigate efficacy as well as to understand and potentially overcome primary and acquired resistance mechanisms of alectinib in glioblastoma. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carbazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Glioblastoma

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Piperidines

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 31776900
DOI: 10.1007/s11060-019-03348-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.PMID 31776900Read ↗

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor TrametinibSemantic proximity Read ↗

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.Semantic proximity Read ↗

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategiesSemantic proximity Read ↗

Adaptive Kinase Signalling Enables Escape from Small Molecule Inhibition in GlioblastomaSemantic proximity Read ↗

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma CellsSemantic proximity Read ↗

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity Read ↗

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Semantic proximity Read ↗

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.Semantic proximity Read ↗

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeuticsSemantic proximity Read ↗

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.